

[Efavirenz + emtricitabine + tenofovir](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.2. Antiretrovirals](#) [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: [J05AR06](#)

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

ICD11 code: [1C62.Z](#)

INN

Efavirenz + emtricitabine + tenofovir

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

EML status history

First added in 2007 ([TRS 946](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[efavirenz + lamivudine + tenofovir](#) (ATC codes: [J05AR11](#))

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Efavirenz + emtricitabine + tenofovir](#)

DrugBank

[Efavirenz](#),

[Emtricitabine](#),

[Tenofovir disoproxil](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.